ResMed Chairman & CEO Michael Farrell Executes Scheduled 10b5-1 Option Exercise and Sale

Insider Transaction Overview

On September 8, 2026, Michael J. Farrell, Chairman and CEO of ResMed Inc. ($RMD), executed a routine option exercise and subsequent sale of 4,991 shares of common stock.

Key Transaction Highlights

• Exercise: Exercised stock options for 4,991 shares at an exercise price of $146.34 per share.
• Sale: Sold 4,991 shares at a weighted-average price of $222.4385 per share (range: $220.680 – $225.390), generating gross proceeds of approximately $1.11 million.
• Trading Plan: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on October 31, 2024.
• Remaining Holdings: Following the transaction, Farrell retains 466,256 shares directly and 2,090 shares indirectly via the Lisette and Michael Farrell Family Trust, along with 9,984 remaining options from the underlying grant.

Market Impact & Significance

This transaction represents a standard, pre-planned option exercise and sale ahead of the option's November 2026 expiration date. Farrell's core direct equity ownership remains substantially intact at over 466,000 shares, indicating this trade carries Low informational significance for investors.